Tushar Desai, MD
Pulmonary Disease · Palo Alto, CANPI 1114075439
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $500 of the $500 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Genentech, Inc.. That places this record below the midpoint for pulmonary disease clinicians in CA, where the typical reported total is $1,248.
Across 1 payment — averaging $500.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$500
Across 8 payments — averaging $214,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$1000K
- Genentech, Inc.$719K
What the payments were for
- Consulting fees$500100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $500 |
How this compares
$500 in reported general payments places this provider in the 35th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $294,436 |
| Mycophenolate Mofetil | 23 | $2,099 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $319 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Palo Alto
- Vinicio de Jesus PerezPalo Alto$116K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.